A Phase 4 interventional study of Acthar Gel and Placebo in Sarcoidosis, Pulmonary, sponsored by Mallinckrodt. Completed at 29 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-02-27.
Sponsored by Mallinckrodt · Phase 4, Interventional, and Treatment
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis.
Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their assigned shot twice a week for 24 weeks.
All participants who complete the 24-week treatment period will be eligible to receive Acthar Gel for 24 more weeks, even if they were originally in the placebo group.
Exclusion Criteria:
Participants received Acthar Gel as a 1 milliliter (mL) injection under the skin, twice weekly, for 24 weeks in the double-blind treatment (DBT) phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional open-label extension (OLE) phase.
Drug: Acthar Gel
Participants received Acthar Gel matching placebo as a 1 mL injection under the skin, twice weekly, for 24 weeks in the DBT phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional OLE phase.
Drug: Acthar Gel · Drug: Placebo
Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
Also known as: H.P. Acthar Gel, Repository Corticotropin Injection
Placebo gel for SC injection
Also known as: Matching Placebo
DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24
Forced vital capacity (FVC) is a pulmonary function test parameter that indicates the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It's measured by spirometry, which is a common breathing test to check lung function. Based on the absolute change of percent predicted, FVC was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], or * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on FVC, a Pulmonary Function Test Parameter at Week 48
Forced vital capacity (FVC) is a pulmonary function test parameter that indicates the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It's measured by spirometry, which is a common breathing test to check lung function. Based on the absolute change of percent predicted, FVC was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], or * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 48
DBT: Number of Participants in Each Category of Assessment Based on the Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), a Pulmonary Function Test Parameter at Week 24
The diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in the blood. Participants are asked to fully inhale a low concentration of carbon monoxide and an inert tracer gas. Based on the absolute change of percent predicted, DLCO was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on the DLCO, a Pulmonary Function Test Parameter at Week 48
The diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in the blood. Participants are asked to fully inhale a low concentration of carbon monoxide and an inert tracer gas. Based on the absolute change of percent predicted, DLCO was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 48
DBT: Number of Participants in Each Category of Assessment Based on High Resolution Computer Tomography (HRCT) at Week 24
High-resolution computer tomography (HRCT) is a type of computed tomography (CT) with specific techniques to enhance image resolution. It is used in the diagnosis of various health problems, most commonly for lung disease. These images show cross sections (slices) through the lungs. HRCT imaging was evaluated by the investigator/radiologist and the central reader to determine if the condition is improved (+1), unchanged (0), or worse (-1). An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on HRCT at Week 48
High-resolution computer tomography (HRCT) is a type of computed tomography (CT) with specific techniques to enhance image resolution. It is used in the diagnosis of various health problems, most commonly for lung disease. These images show cross sections (slices) through the lungs. HRCT imaging was evaluated by the investigator/radiologist and the central reader to determine if the condition is improved (+1), unchanged (0), or worse (-1). An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 48
DBT: Number of Participants in Each Category of Assessment Based on the King's Sarcoidosis Questionnaire (KSQ) (General Health), a Quality of Life Parameter at Week 24
King's sarcoidosis questionnaire (KSQ) (General Health) is a 28-item questionnaire for participants to indicate the status of their sarcoidosis and treatment. Each item was answered on a 7-point scale where 1 means the participant experiences the symptom all the time and 7 means the participant does not experience the symptom at all. Higher scores indicate improvement, and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≥ 4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≤ -4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on the KSQ (General Health), a Quality of Life Parameter at Week 48
King's sarcoidosis questionnaire (KSQ) (General Health) is a 28-item questionnaire for participants to indicate the status of their sarcoidosis and treatment. Each item was answered on a 7-point scale where 1 means the participant experiences the symptom all the time and 7 means the participant does not experience the symptom at all. Higher scores indicate improvement, and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≥ 4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≤ -4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 48
DBT: Number of Participants in Each Category of Assessment Based on the Fatigue Assessment Score (FAS), a Quality of Life Parameter at Week 24
The fatigue assessment score (FAS) is a 10-item checklist for participants to indicate the level of their fatigue. Each item was answered on a 5-point scale where 1 means the participant does not experience the symptom all and 5 means the participant experiences the symptom all the time. Lower scores indicate improvement (less fatigue) and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≤ -4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≥ 4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on FAS, a Quality of Life Parameter at Week 48
The fatigue assessment score (FAS) is a 10-item checklist for participants to indicate the level of their fatigue. Each item was answered on a 5-point scale where 1 means the participant does not experience the symptom all and 5 means the participant experiences the symptom all the time. Lower scores indicate improvement (less fatigue) and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≤ -4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≥ 4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
Time frame: Week 48
DBT: Number of Participants in Each Category of Assessment Based on Corticosteroid Taper Score in Participants Receiving Each Dose of Prednisone at Week 24
Corticosteroids are first line treatment for sarcoidosis. Concerns of corticosteroid toxicity led to efforts to taper dose sooner. Participants were clinically evaluated at each visit by investigator and categorized by their condition; dose was tapered using algorithm to take them off prednisone using incremental doses of 40,30,20,10,7.5,5,2.5,0 mg, as explained with each category below. * Improved: When condition improved, reduce dose by 1 level * Unchanged: 1. When stable condition without toxicity: At first stable visit they continue same dose; at second stable visit, reduce dose by 1 level 2. When stable condition with toxicity: toxicity is treated; reduce dose by 1 level * Deteriorate: When worsening condition, increase dose by 1 or 2 levels but not \>40mg/day Dose tapering was done based on the participant's clinical condition. Category "Missing Assessment" indicates participants who had a missing assessment for this outcome measure.
Time frame: Week 24
OLE: Number of Participants in Each Category of Assessment Based on Corticosteroid Taper Score in Participants Receiving Each Dose of Prednisone at Week 48
Corticosteroids are first line treatment for sarcoidosis. Concerns of corticosteroid toxicity led to efforts to taper dose sooner. Participants were clinically evaluated at each visit by investigator and categorized by their condition; dose was tapered using algorithm to take them off prednisone using incremental doses of 40,30,20,10,7.5,5,2.5,0 mg, as explained with each category below. * Improved: When condition improved, reduce dose by 1 level * Unchanged: 1. When stable condition without toxicity: At first stable visit they continue same dose; at second stable visit, reduce dose by 1 level 2. When stable condition with toxicity: toxicity is treated; reduce dose by 1 level * Deteriorate: When worsening condition, increase dose by 1 or 2 levels but not \>40mg/day Dose tapering was done based on the participant's clinical condition. Category "Missing Assessment" indicates participants who had a missing assessment for this outcome measure.
Time frame: Week 48
Participants took part in the study at 35 investigative sites in the United States from 21 February 2018 to 15 November 2021.
| Milestone | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Started | 27 | 28 |
| Modified intent-to-treat population (mitt) | 27 | 28 |
| Safety population | 27 | 28 |
| Completed | 24 | 25 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Milestone | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Started | 22 | 25 |
| Open-label safety population | 22 | 25 |
| Completed | 17 | 23 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Forced vital capacity (FVC) is a pulmonary function test parameter that indicates the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It's measured by spirometry, which is a common breathing test to check lung function. Based on the absolute change of percent predicted, FVC was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], or * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 10 | 7 |
| Unchanged | 12 | 12 |
| Deteriorate | 1 | 3 |
| Missing Assessment | 4 | 6 |
Forced vital capacity (FVC) is a pulmonary function test parameter that indicates the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. It's measured by spirometry, which is a common breathing test to check lung function. Based on the absolute change of percent predicted, FVC was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], or * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 2 | 6 |
| Unchanged | 13 | 11 |
| Deteriorate | 1 | 3 |
| Missing Assessment | 6 | 5 |
The diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in the blood. Participants are asked to fully inhale a low concentration of carbon monoxide and an inert tracer gas. Based on the absolute change of percent predicted, DLCO was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 5 | 4 |
| Unchanged | 11 | 11 |
| Deteriorate | 7 | 7 |
| Missing Assessment | 4 | 6 |
The diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in the blood. Participants are asked to fully inhale a low concentration of carbon monoxide and an inert tracer gas. Based on the absolute change of percent predicted, DLCO was evaluated to determine if the condition is: * Improved (+1) \[≥ 5% absolute change\] * Unchanged (0) \[\>- 5% to \< 5% absolute change\], * Worse (-1) \[≤ -5% absolute change\] An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 9 | 6 |
| Unchanged | 3 | 6 |
| Deteriorate | 4 | 8 |
| Missing Assessment | 6 | 5 |
High-resolution computer tomography (HRCT) is a type of computed tomography (CT) with specific techniques to enhance image resolution. It is used in the diagnosis of various health problems, most commonly for lung disease. These images show cross sections (slices) through the lungs. HRCT imaging was evaluated by the investigator/radiologist and the central reader to determine if the condition is improved (+1), unchanged (0), or worse (-1). An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 2 | 1 |
| Unchanged | 22 | 18 |
| Deteriorate | 0 | 4 |
| Missing Assessment | 3 | 5 |
High-resolution computer tomography (HRCT) is a type of computed tomography (CT) with specific techniques to enhance image resolution. It is used in the diagnosis of various health problems, most commonly for lung disease. These images show cross sections (slices) through the lungs. HRCT imaging was evaluated by the investigator/radiologist and the central reader to determine if the condition is improved (+1), unchanged (0), or worse (-1). An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 1 | 6 |
| Unchanged | 13 | 13 |
| Deteriorate | 1 | 2 |
| Missing Assessment | 7 | 4 |
King's sarcoidosis questionnaire (KSQ) (General Health) is a 28-item questionnaire for participants to indicate the status of their sarcoidosis and treatment. Each item was answered on a 7-point scale where 1 means the participant experiences the symptom all the time and 7 means the participant does not experience the symptom at all. Higher scores indicate improvement, and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≥ 4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≤ -4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 11 | 7 |
| Unchanged | 3 | 8 |
| Deteriorate | 10 | 9 |
| Missing Assessment | 3 | 4 |
King's sarcoidosis questionnaire (KSQ) (General Health) is a 28-item questionnaire for participants to indicate the status of their sarcoidosis and treatment. Each item was answered on a 7-point scale where 1 means the participant experiences the symptom all the time and 7 means the participant does not experience the symptom at all. Higher scores indicate improvement, and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≥ 4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≤ -4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 8 | 8 |
| Unchanged | 2 | 5 |
| Deteriorate | 6 | 9 |
| Missing Assessment | 6 | 3 |
The fatigue assessment score (FAS) is a 10-item checklist for participants to indicate the level of their fatigue. Each item was answered on a 5-point scale where 1 means the participant does not experience the symptom all and 5 means the participant experiences the symptom all the time. Lower scores indicate improvement (less fatigue) and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≤ -4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≥ 4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 6 | 6 |
| Unchanged | 12 | 11 |
| Deteriorate | 6 | 7 |
| Missing Assessment | 3 | 4 |
The fatigue assessment score (FAS) is a 10-item checklist for participants to indicate the level of their fatigue. Each item was answered on a 5-point scale where 1 means the participant does not experience the symptom all and 5 means the participant experiences the symptom all the time. Lower scores indicate improvement (less fatigue) and a change of 4 points is considered clinically meaningful. The score on the scale was evaluated to determine if the condition is: * Improved (+1) based on a change of ≤ -4 points * Unchanged (0) based on a change of \>- 4 to \< 4 points * Worse (-1) based on a change of ≥ 4 points An additional category "Missing Assessment" indicates the participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 7 | 4 |
| Unchanged | 5 | 13 |
| Deteriorate | 4 | 5 |
| Missing Assessment | 6 | 3 |
Corticosteroids are first line treatment for sarcoidosis. Concerns of corticosteroid toxicity led to efforts to taper dose sooner. Participants were clinically evaluated at each visit by investigator and categorized by their condition; dose was tapered using algorithm to take them off prednisone using incremental doses of 40,30,20,10,7.5,5,2.5,0 mg, as explained with each category below. * Improved: When condition improved, reduce dose by 1 level * Unchanged: 1. When stable condition without toxicity: At first stable visit they continue same dose; at second stable visit, reduce dose by 1 level 2. When stable condition with toxicity: toxicity is treated; reduce dose by 1 level * Deteriorate: When worsening condition, increase dose by 1 or 2 levels but not \>40mg/day Dose tapering was done based on the participant's clinical condition. Category "Missing Assessment" indicates participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 17 | 21 |
| Unchanged | 8 | 4 |
| Deteriorate | 0 | 0 |
| Missing Assessment | 2 | 3 |
Corticosteroids are first line treatment for sarcoidosis. Concerns of corticosteroid toxicity led to efforts to taper dose sooner. Participants were clinically evaluated at each visit by investigator and categorized by their condition; dose was tapered using algorithm to take them off prednisone using incremental doses of 40,30,20,10,7.5,5,2.5,0 mg, as explained with each category below. * Improved: When condition improved, reduce dose by 1 level * Unchanged: 1. When stable condition without toxicity: At first stable visit they continue same dose; at second stable visit, reduce dose by 1 level 2. When stable condition with toxicity: toxicity is treated; reduce dose by 1 level * Deteriorate: When worsening condition, increase dose by 1 or 2 levels but not \>40mg/day Dose tapering was done based on the participant's clinical condition. Category "Missing Assessment" indicates participants who had a missing assessment for this outcome measure.
| Participants | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE |
|---|---|---|
| Improved | 15 | 19 |
| Unchanged | 5 | 5 |
| Deteriorate | 0 | 0 |
| Missing Assessment | 2 | 1 |
Collected over From the signing of Informed Consent Form (ICF) to follow up visit, 4 weeks after the last dose of study drug (approximately 52 weeks for a participant). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT: Acthar Gel 80 U (1 mL) | 0/27 (0%) | 4/27 (14.8%) | 22/27 (81.5%) |
| DBT: Placebo | 0/28 (0%) | 3/28 (10.7%) | 25/28 (89.3%) |
| OLE: Acthar Gel 80 U (1 mL) [Received Acthar in DBT] | 0/22 (0%) | 6/22 (27.3%) | 14/22 (63.6%) |
| OLE: Acthar Gel 80 U (1 mL) [Received Placebo in DBT] | 0/25 (0%) | 0/25 (0%) | 14/25 (56%) |
| Event | DBT: Acthar Gel 80 U (1 mL) | DBT: Placebo | OLE: Acthar Gel 80 U (1 mL) [Received Acthar in DBT] | OLE: Acthar Gel 80 U (1 mL) [Received Placebo in DBT] |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/27 | 1/28 | 1/22 | 0/25 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/27 | 0/28 | 1/22 | 0/25 |
| Haemoglobin decreasedInvestigations | 0/27 | 0/28 | 1/22 | 0/25 |
| Metastatic renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 0/28 | 1/22 | 0/25 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/27 | 0/28 | 1/22 | 0/25 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/27 | 0/28 | 1/22 | 0/25 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/27 | 0/28 | 1/22 | 0/25 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/27 | 0/28 | 1/22 | 0/25 |
| UveitisEye disorders | 1/27 | 0/28 | 0/22 | 0/25 |
| CholelithiasisHepatobiliary disorders | 1/27 | 0/28 | 0/22 | 0/25 |
| Event | DBT: Acthar Gel 80 U (1 mL) | DBT: Placebo | OLE: Acthar Gel 80 U (1 mL) [Received Acthar in DBT] | OLE: Acthar Gel 80 U (1 mL) [Received Placebo in DBT] |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/27 | 8/28 | 2/22 | 1/25 |
| HeadacheNervous system disorders | 4/27 | 7/28 | 1/22 | 0/25 |
| Diabetes mellitusMetabolism and nutrition disorders | 6/27 | 1/28 | 1/22 | 1/25 |
| Upper respiratory tract infectionInfections and infestations | 5/27 | 2/28 | 1/22 | 0/25 |
| Injection site bruisingGeneral disorders | 2/27 | 5/28 | 1/22 | 2/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/27 | 5/28 | 3/22 | 2/25 |
| FatigueGeneral disorders | 4/27 | 4/28 | 2/22 | 2/25 |
| NauseaGastrointestinal disorders | 2/27 | 2/28 | 3/22 | 1/25 |
| BronchitisInfections and infestations | 1/27 | 2/28 | 3/22 | 0/25 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/27 | 1/28 | 1/22 | 3/25 |
The safety population included all randomized participants who received at least 1 dose of IMP.
| Age, Continuous(years) | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE | Total |
|---|---|---|---|
| Mean | 53.6 ± 9.07 | 54.8 ± 11.33 | 54.2 ± 10.21 |
| Sex: Female, Male(Participants) | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE | Total |
|---|---|---|---|
| Female | 11 | 15 | 26 |
| Male | 16 | 13 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 23 | 24 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 13 | 19 |
| White | 21 | 15 | 36 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Acthar Gel in DBT Then Acthar Gel in OLE | Placebo in DBT Then Acthar Gel in OLE | Total |
|---|---|---|---|
| United States | 27 | 28 | 55 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mallinckrodt